Milestone Pharmaceuticals Stock (NASDAQ: MIST)

Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

News

MASS

908 Devices Launches VipIR, Industry-First 3-in-1 Handheld Analyzer With Integrated FTIR, Raman, and Smart Spectral Processing for Field Chemical ID

Larimar Therapeutics, Inc. (Larimar) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication of two peer-reviewed articles highlighting nonclinical data on the therapeutic potential, pharmacology, and mechanism of action of nomlabofusp as a novel frataxin (FXN) protein replacement therapy designed to address the underlying cause of Friedreich's ataxia (FA). These data were included in the briefing package reviewed by the U.S. Food and Drug Administration (FDA) in support of potentially using skin FXN concentrations as a reasonably likely surrogate endpoint (RLSE) for Larimar's registrational program seeking accelerated approval for nomlabofusp.
The articles, now available online, are titled:
<ul>
<li>"Pharmacokinetics and Pharmacodynamics of Nomlabofusp in Non‑clinical Studies of Friedreich's Ataxia" (<a href="https://link.springer.com/article/10.1208/s12248-025-01093-y">link</a>)</li>
<li>"Nomlabofusp, a Fusion Protein of Human Frataxin and a Cell Penetrant Peptide, Delivers Mature and Functional Frataxin into Mitochondria" (<a href="https://link.springer.com/article/10.1208/s12248-025-01054-5">link</a>)</li>
</ul>

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Highlights Data for Rare Disease Drug Nomlabofusp in FDA Briefing

Driven by retailer demand for greater food safety and transparency, cheese producers worldwide are lining up to join the rapidly growing ReposiTrak Traceability Network
ReposiTrak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 31 cheese suppliers to the queue of companies joining the ReposiTrak Traceability Network&#xAE; (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.

TRAK

ReposiTrak Adds 31 Cheese Suppliers To Queue Of Companies Joining ReposiTrak Traceability Network

JinkoSolar Commissions 21.6 MWh Energy Storage Systems With Distributed Energy Infrastructure Under SMART Program

Biotech

General

BCLI

BrainStorm Cell Therapeutics Acknowledges FDA Consideration Of Citizen Petition Requesting New Review Of Data Supporting NurOwn; Says Will Continue With Planned Phase 3b Trial

Today, IBM (NYSE:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2864195-1&amp;h=964409748&amp;u=http%3A%2F%2Fwww.ibm.com%2Finvestor&amp;a=IBM">IBM</a>)&nbsp;revealed IBM Power11, the next generation of IBM&#xAE; Power&#xAE; servers. Redesigned with innovations across its processor, hardware architecture, and virtualization software stack, Power11 is designed to deliver the availability, resiliency, performance, and scalability enterprises demand, for seamless hybrid deployment on-premises or in IBM Cloud.
&nbsp;
Organizations across industries have long run their most mission-critical, data-intensive workloads on IBM Power, most notably those within the banking, healthcare, retail, and government spaces. Now, enterprises face an onslaught of new technologies and solutions as they transition into the age of AI. IDC found that one billion new logical applications are expected by 2028, and the proliferation of these systems poses new complexities for companies.1 IBM built Power11 to deliver simplified, always-on operations with hybrid cloud flexibility for enterprises to maintain competitiveness in the AI era.
Power11 is designed to be the most resilient server in the history of the IBM Power platform, with 99.9999% of uptime.2 Together with zero planned downtime for system maintenance3 and less than one-minute guaranteed ransomware threat detection with IBM Power Cyber Vault,&nbsp;4 Power11 sets a new bar for business continuity, addressing both planned and cyber-incident-related downtime.&nbsp;
For the first time ever, the Power11 general availability will simultaneously include high-end, mid-range, and entry servers as well as IBM Power Virtual Server in IBM Cloud. IBM Power Virtual Server offers a fast path to the cloud for Power workloads, and is certified as a hyperscaler platform for <a href="https://www.ibm.com/cloud/rise-with-sap">RISE with SAP</a>.&nbsp; Power11 will also be the first IBM Power server to support the IBM Spyre Accelerator, IBM's system-on-a-chip available Q4 2025 that is purpose-built for today's AI-intensive inference workloads. Available across IBM's enterprise systems portfolio, including Power11, <a href="https://www.ibm.com/products/z17">IBM z17</a>, and <a href="https://www.ibm.com/products/linuxone-5">LinuxONE 5</a>, Spyre will deliver advanced AI acceleration to help organizations scale AI across hybrid cloud environments.
With support for autonomous operations, Power11 delivers intelligent performance gains that reduce complexity and improve workload efficiency. Power11 offers up to 55% better core performance compared to Power95 and has up to 45% more capacity with higher core counts in entry and mid-range systems compared to Power10.6 &nbsp;This upgraded performance means that with Power11, enterprises are positioned to achieve enhanced flexibility and security, to transform their enterprise processes through automation.

IBM Unveils Power11 Servers With AI Acceleration and 99.9999% Uptime for Enterprise Workloads

Aeva's 4D LiDAR Technology Enables Advanced Intrusion Detection Near Perimeters
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aeva.com%2F&amp;esheet=54287123&amp;newsitemid=20250708943634&amp;lan=en-US&amp;anchor=Aeva&amp;index=1&amp;md5=ea0334bd3a85954c558815636a582429">Aeva</a>&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>), a leader in next-generation sensing and perception systems, today announced that Sandia National Laboratories has completed its evaluation phase of Aeva's 4D LiDAR technology. Following the previously announced selection of Aeva's technology, Sandia is planning to test Aeva's technology at a U.S. nuclear reactor site to evaluate its performance to enhance security and assess threat detection capabilities. These include for potential intrusions in the perimeter areas of the facility, such as water intakes that are important for safe reactor operation.

AEVA

Aeva Says Sandia National Laboratories Completes Evaluation Phase Of Aeva's 4D LiDAR Technology

Redwire Completes Integration of Hammerhead Spacecraft for ESA Tech Demo Mission, Marks Second Platform Milestone at Belgium Facility This Summer

To enhance the quality of life for its residents, Tatweer Misr, one of Egypt's leading real estate developers, has selected Otis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>), the world's leading elevator and escalator manufacturing, installation and service company, to supply and install smart vertical mobility solutions across its urban communities. Tatweer Misr's current engagement with Otis represents six projects and 1,250 elevators over six years.
&nbsp;
Since its establishment in 2014, Tatweer Misr has been at the forefront of real estate development in Egypt, continuously setting new benchmarks in urban development. The company is known for developing sustainable and smart urban communities. Through this collaboration, Tatweer Misr will integrate Otis's Gen2&#xAE; elevator systems, which offer energy efficiency, superior ride quality, and space-saving design, into Tatweer Misr's portfolio of six iconic projects that have established the company's footprint across Egypt's most strategic locations. These include the award-winning IL Monte Galala on the Red Sea; North Coast landmarks Fouka Bay, D-Bay, and Salt, each redefining coastal living; Bloomfields, a mixed-use, first-home community in Mostakbal City, East Cairo; Rivers, an upscale residential development in West Cairo, each designed to redefine modern, sustainable living.

OTIS

Otis Lands Deal to Install 1,250 Smart Elevators in Egypt's Top Urban Projects

PARA

Paramount Global Says Nickelodeon Added Spin Master's Unicorn Academy and Vida the Vet to July Lineup, Marking US Linear Debuts on Nickelodeon and Nick Jr.

EVGN

Evogene Completes Sale Of Lavie Bio Assets And MicroBoost AI Platform To ICL Group

Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>, <a href="https://www.globenewswire.com/Tracker?data=YIAvPI1Tp5RUL4j4EHFRaR_pm2cv7wJnKUs8dK9QHLFgGor0QOleG8-0VVeCjFTSYqs680G5KO0neTPfeAtnlg==">www.mrcy.com</a>))), a technology company that delivers mission-critical processing to the edge, today announced it received two new production awards in June totaling $36.9 million for ground-based radar programs that leverage its Common Processing Architecture and cybersecurity software from recently acquired Star Lab.

Government

Regulations

MRCY

Mercury Systems Wins $36.9M in Defense Contracts for Ground-Based Radar Tech

Keybanc analyst Sophie Karp upgrades SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Underweight to Sector Weight.

Upgrades

Analyst Ratings

SEDG

Keybanc Upgrades SolarEdge Technologies to Sector Weight

EPRX

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled RESOLVE Trial for Eosinophilic Esophagitis, Targeting Pivotal Study Readiness by Q3 2026

CRVO

CervoMed To Present Results From RewinD-LB Phase 2b Study Of Neflamapimod In Dementia With Lewy Bodies, At AAIC 2025

Events

CervoMed To Present At Alzheimer's Association International Congress 2025 On July 27

<a href="https://www.globenewswire.com/Tracker?data=Sjm7HxugM0aKuCdtig1s0NCVhX9IUz-W8Mp8zVyUhHXfQqg2WbsApG6GwJU8XSA3lZstKPsqrfZBYjvWSvGs2veBvziXAsBoPL84_T7GNdw=">Plymouth Industrial REIT</a>, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) (the "Company" or "Plymouth") provided an activity update for the second quarter of 2025. The Company also announced details for its second quarter earnings conference call and webcast to be held on August 7, 2025.
Leasing Activity Leases commencing during the second quarter ended June 30, 2025, which have terms of at least six months, totaled an aggregate of 1,453,757 square feet. These leases included:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Leases Commenced</td>
<td>Type</td>
<td>Square Footage</td>
<td>Percent</td>
<td colspan="3">Expiring Rent</td>
<td colspan="3">New Rent</td>
<td>Cash Rent Spread</td>
</tr>
<tr>
<td>Q2</td>
<td>Renewal</td>
<td>1,159,623</td>
<td>79.8%</td>
<td>$</td>
<td>5.00</td>
<td>$</td>
<td>5.45</td>
<td>9.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New</td>
<td>294,134</td>
<td>20.2%</td>
<td>$</td>
<td>4.92</td>
<td>$</td>
<td>5.61</td>
<td>14.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Total</td>
<td>1,453,757</td>
<td>100%</td>
<td>$</td>
<td>4.98</td>
<td>$</td>
<td>5.48</td>
<td>10.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
An additional 239,500 square feet has been leased on a short-term basis with auto-renewals and landlord kick-out options.
Total executed leases commencing during 2025, which had terms of at least six months, totaled an aggregate of 5,811,172 square feet. These leases, which represent 67.5% of total 2025 expirations, include:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>2025 Commencements</td>
<td>Type</td>
<td>Square Footage</td>
<td>Percent</td>
<td colspan="3">Expiring Rent</td>
<td colspan="3">New Rent&nbsp;</td>
<td>Cash Rent Spread</td>
</tr>
<tr>
<td>Renewal</td>
<td>4,095,835</td>
<td>70.5%</td>
<td>$</td>
<td>4.47</td>
<td>$</td>
<td>5.13</td>
<td>14.7%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New</td>
<td>1,715,337</td>
<td>29.5%</td>
<td>$</td>
<td>4.27</td>
<td>$</td>
<td>4.64</td>
<td>8.7%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Total</td>
<td>5,811,172</td>
<td>100%</td>
<td>$</td>
<td>4.41</td>
<td>$</td>
<td>4.98</td>
<td>13.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Excluding the effect of the St. Louis Lease (as defined below), which commenced in the first quarter, rental rates under these leases would have reflected a 15.8% increase with new leases reflecting a 19.9% increase on a cash basis. The Company executed a two-year lease at its 769,500-square-foot Class A industrial building in the Metro East submarket of St. Louis, Missouri that commenced on January 15, 2025 (the "St. Louis Lease"). The lease is for 600,000 square feet during the first year and 450,000 square feet during the second year with a major international logistics service provider. This deal was done on an "as is" basis with no abatements making it attractive from a net lease rate perspective. While we continue to actively market the balance of the building, the existing tenant has leased the remaining 169,500 square feet on a rolling 90-day basis with landlord kick-out rights.
Total executed leases commencing in 2026, which have terms of at least six months, total an aggregate of 1,052,775 square feet, representing 13.7% of total 2026 expirations.
Same store occupancy at June 30, 2025, was 95.0%, while total portfolio occupancy at June 30, 2025, was 94.6%. Total portfolio occupancy changes from last quarter include:
<ul>
<li>50-basis-point net positive impact from leasing in St. Louis;</li>
<li>40-basis-point net positive impact from leasing in Cleveland;</li>
<li>40-basis-point net positive impact from leasing in Cincinnati;</li>
<li>Net 30-basis-point positive impact from acquisitions activity in the quarter; and</li>
<li>Net negative 130 basis-point impact from known leasing roll-over in Memphis (for which replacement interest has been high). &nbsp;</li>
</ul>
Acquisition Activity During the second quarter of 2025, Plymouth closed on the acquisition of 22 industrial buildings totaling 2.05 million square feet for a total of $204.7 million. Together, these properties are 97.1% leased and feature a weighted average remaining lease term of 2.6 years. The second quarter activity comprises the following:
<ul>
<li>100,420 square foot industrial building in southwest Atlanta, Georgia for $11.7 million at an expected initial net operating income ("NOI") yield of 6.95%; and</li>
<li>1.95 million square foot industrial portfolio encompassing 21 buildings located across Columbus, Cincinnati, and Cleveland for $193.0 million.</li>
</ul>
The Company used its existing unsecured line of credit to fund the abovementioned acquisitions. As of July 8, 2025, there is approximately $285.8 million of capacity on the line of credit.
Capital Markets Activity Under the Company's previously announced share repurchase program, through June 30, 2025, the Company has acquired and settled 805,394 shares of common stock at an average price per share of approximately $16.26.

PLYM

Plymouth Industrial Leases Nearly 5.8M Sq. Ft. in 2025, Rents Rise 13% on Renewals

<ul>
<li>More Than Doubles H2O America's Connections in Texas and Increases Exposure to High Growth Houston Region</li>
<li>Drives Scale, Increases Financial and Operational Diversification, and Enhances Value and Reliability for Customers, Communities, and All Stakeholders</li>
<li>Transaction Expected to be Accretive to Long-Term EPS Growth Rate; Texas Projected to Become Second Largest Utility Operation of H2O America by 20281</li>
<li>Company to Host Investor Webcast Today at 5:30 a.m. PT / 7:30 a.m. CT / 8:30 a.m. ET; Files Investor Presentation Highlighting Benefits of Proposed Combination</li>
</ul>

H2O America Acquires Quadvest In $540M Deal, More Than Doubling Texas Connections

Keybanc analyst Sophie Karp upgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Underweight to Sector Weight.

Keybanc Upgrades Sunrun to Sector Weight

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54286814&amp;newsitemid=20250708428715&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=603300247059cb367a81bfc1bb8c81dc">Amylyx Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) ("Amylyx" or the "Company") today announced that it will host an investor event at the Endocrine Society's annual meeting (ENDO 2025) on Sunday, July 13, 2025, at 6:00 p.m. PT, both in-person in San Francisco, California and virtually. Speakers will discuss the current burden of post-bariatric hypoglycemia (PBH) and background on avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation. Speakers will also review new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide in post-bariatric hypoglycemia, which will be presented during ENDO 2025. These data include composite rates of Level 2 and 3 hypoglycemic events in both trials as well as new pharmacokinetic (PK) and pharmacodynamic (PD) data demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period.
Amylyx' management team will be joined by the following experts at the event:
<ul>
<li>Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY clinical trial, Co-Lead Investigator of the Phase 2 PREVENT Clinical Trial, and Clinical Associate Professor of Medicine at Stanford University School of Medicine</li>
<li>Helen Lawler, MD, Investigator on the LUCIDITY Clinical Trial, Co-Lead Investigator of the Phase 2 PREVENT Clinical Trial, and Associate Professor of Medicine in Endocrinology at University of Colorado at Denver School of Medicine</li>
<li>Colleen Craig, MD, Co-lead Investigator of Proof-of-Concept and First-in-Human Studies of Avexitide in PBH, led the avexitide development program during the Phase 2 PREVENT Clinical Trial, and Scientific Advisor and Consultant for Amylyx</li>
</ul>

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx to Spotlight Breakthrough Hypoglycemia Drug Avexitide at ENDO 2025 Investor Event

Legal

Press Releases

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

FDA Issues Complete Response Letter for Etripamil for PSVT

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Comments

Milestone Pharmaceuticals

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL